![Nick Cetateanu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Nick Cetateanu
Geschäftsführer bei Purespring Therapeutics Ltd.
Aktive Positionen von Nick Cetateanu
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Purespring Therapeutics Ltd.
![]() Purespring Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Purespring Therapeutics Ltd. provides biotechnological research and experimental development services. The company was founded on April 1, 2020 and is headquartered in London, the United Kingdom. | Geschäftsführer | 26.07.2022 | - |
Karriereverlauf von Nick Cetateanu
Ehemalige bekannte Positionen von Nick Cetateanu
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ORCHARD THERAPEUTICS PLC | Corporate Officer/Principal | - | - |
Statistik
International
Vereinigtes Königreich | 3 |
Operativ
Chief Operating Officer | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Commercial Services | 2 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Purespring Therapeutics Ltd.
![]() Purespring Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Purespring Therapeutics Ltd. provides biotechnological research and experimental development services. The company was founded on April 1, 2020 and is headquartered in London, the United Kingdom. | Commercial Services |
Orchard Therapeutics Plc
![]() Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Nick Cetateanu
- Erfahrung